Renin–angiotensin–aldosterone system inhibitors and COVID-19
Open Access
- 24 April 2020
- journal article
- editorial
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 192 (20), E553-E554
- https://doi.org/10.1503/cmaj.200619
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19Circulation Research, 2020
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19The New England Journal of Medicine, 2020
- COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor BlockersJAMA, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Preventing a covid-19 pandemicBMJ, 2020
- The 2017 Clinical Practice Guideline for High Blood PressureJAMA, 2017
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007